Human interferon-alpha increases the cytotoxic effect of CD56cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines

Cytotherapy

Volumn 14, Issue 10, 2012, Pages 1245-1257

  Durrieu, Ludovic ^a,b   Gregoire Gauthier, Joëlle ^a,b   Dieng, Mame Massar ^a   Fontaine, François ^a   Le Deist, Françoise ^a,b   Haddad, Elie ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

B lineage acute lymphoblastic leukemia; cytokine induced killer cells; graft versus host disease; graft versus leukemia; human interferon alpha

Indexed keywords

CD56 ANTIGEN; CD69 ANTIGEN; PHOSPHATE BUFFERED SALINE; RECOMBINANT ALPHA INTERFERON; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOCYTOTOXICITY; MONONUCLEAR CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UMBILICAL CORD BLOOD; UPREGULATION;

EID: 84867653693     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.714864     Document Type: Article

References (53)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 605-15.
2. Pui C H, Evans W E. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166-78.
3. Uderzo C, Conter V, Dini G, Locatelli F, Miniero R, Tamaro P. Treatment of childhood acute lymphoblastic leukemia after the first relapse: Curative strategies. Haematologica. 2001; 86: 1-7.
4. National Marrow Donor Program. Trends in Allogeneic Transplants. Available from: Http://marrow.org/Physicians/Unrelated-Search-and-Transplant/ Trends-in-Allo-Transplants.aspx. (accessed May, 2012).
5. Gluckman E, Rocha V. Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant. 2008; 41(Suppl 2): S80-2.
6. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008; 112: 4371-83.
7. Collins RH J r, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000; 26: 511-6.
8. Kolb H J, Schattenberg A, Goldman J M, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995; 86: 2041-50.
9. Choi SJ, Lee JH, Kim S, Lee YS, Seol M, Ryu SG, et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A prospective study. Bone Marrow Transplant. 2005; 36: 163-9.
10. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. JExp Med. 1991; 174: 139-49.
11. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993; 21: 1673-9.
12. Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, et al. Rapid and massive expansion of cord bloodderived cytokine-induced killer cells: An innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006; 38: 621-7.
13. Verneris M R, Ito M, Baker J, Arshi A, Negrin R S, Shizuru JA. Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8 -NK -T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001; 7: 532-42.
14. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003; 101: 640-8.
15. Sweeney T J, Mailander V, Tucker A A, Olomu A B, Zhang W, Cao Y, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA. 1999; 96: 12044-9.
16. Wongkajornsilp A, Somchitprasert T, Butraporn R, Wamanuttajinda V, Kasetsinsombat K, Huabprasert S, et al. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice. Cancer Invest. 2009; 27: 140-8.
17. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokineinduced killer (CIK) cells: Implications for their infusion across major HLA barriers. Int Immunol. 2008; 20: 841-8.
18. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, et al. In vivo trafficking and survival of cytokineinduced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008; 112: 2563-74.
19. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8( -) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001; 97: 2923-31.
20. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol Oncol. 2009; 27: 130-9.
21. Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, et al. Repeated infusions of donor-derived cytokineinduced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study. Haematologica. 2007; 92: 952-9.
22. Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant. 2012; 47: 957-66.
23. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002; 116: 78-86.
24. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol. 2006; 34: 1219-29.
25. Swann J B, Hayakawa Y, Zerafa N, Sheehan K C, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007; 178: 7540-9.
26. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine. 2003; 24: 81-90.
27. Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, et al. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8 -T cell responses against human tumor antigens. J Immunol. 2004; 172: 5363-70.
28. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354: 709-18.
29. Molldrem J J, Lee P P, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000; 6: 1018-23.
30. Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Kabisch A, Lubbert M, et al. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lympho blastic leukemia (Ph -ALL). Leukemia. 2003; 17: 1919-24.
31. Piccaluga P P, Martinelli G, Isidori A, Malagola M, Rondoni M, Paolini S, et al. Long-term molecular complete remission with IFN-alpha in Ph -adult acute lymphoid leukemia patients. Leukemia. 2008; 22: 1617-8.
32. Gregoire-Gauthier J, Durrieu L, Duval A, Fontaine F, Dieng MM, Bourgey M, et al. Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/gammacmouse model. Bone Marrow Transplant. 2012; 47: 439-50.
33. Gregoire-Gauthier J, Selleri S, Fontaine F, Dieng MM, Patey N, Despars G, et al. Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model. Stem Cells Dev. 2012; 21: 1616-26.
34. Schmidt-Wolf I G, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994; 87: 453-8.
35. Liang S, Wei H, Sun R, Tian Z. IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine. 2003; 23: 190-9.
36. Dalle JH, Duval M, Moghrabi A, Wagner E, Vachon MF, Barrette S, et al. Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant. 2004; 33: 605-11.
37. Laurin D, Marin V, Biagi E, Pizzitola I, Agostoni V, Gallot G, et al. Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells. J Biomed Biotechnol. 2010; DOI: 10.1155/2010/234540.
38. Erhardt M, Schmidt-Wolf I G, Sievers E, Frank S, Strehl J, von Lilienfeld-Toal M, et al. Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells. Arch Immunol Ther Exp (Warsz). 2006; 54: 403-9.
39. Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, et al. Type I-IFNs control GVHD and GVL res ponses after transplantation. Blood. 2011; 118: 3399-409.
40. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol. 2001; 31: 3138-46.
41. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. JExp Med. 1999; 189: 1451-60.
42. Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, et al. The cytotoxic potential of interleukin- 15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012; 14: 91-103.
43. Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 2007; 7: 1793-801.
44. Petvises S, Pakakasama S, Wongkajornsilp A, Sirireung S, Panthangkool W, Hongeng S. Ex vivo generation of cytokineinduced killer cells (CD3 -CD56 -) from post-stem cell transplant pediatric patients against autologous Epstein - Barr virus-transformed lymphoblastoid cell lines. Pediatr Transplant. 2007; 11: 511-7.
45. Lu PH, Negrin RS. Anovel population of expanded human CD3 -CD 56 -cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994; 153:1687-96.
46. Kim H M, Lim J, Park S K, Kang J S, Lee K, Lee C W, et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol. 2007; 7: 1802-7.
47. Kim YJ, Lim J, Kang JS, Kim HM, Lee HK, Ryu HS, et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res. 2010; 33: 1789-95.
48. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther. 2009; 9: 831-40.
49. Linn YC, Hui KM. Cytokine-induced NK-like T cells: From bench to bedside. J Biomed Biotechnol. 2010; DOI: 10.1155/2010/435745.
50. Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol. 2011; 11: 449-56.
51. Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Mico C, et al. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant. 2010; 16: 1603-7.
52. Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation. 2009; 87: 1654-8.
53. Cooper N, Rao K, Goulden N, Amrolia P, Veys P. Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias. Br J Haematol. 2012; 156: 550-2.